Method of purifying cardiac hypertrophy factor
US5723585A · kind A · utility
14Cited by
15References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 1995 |
| Grant date | Mar 3, 1998 |
| Priority date | — |
| Expiry date | May 17, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.